*Source: IQVIA Total Prescriptions (TRx) Data October 2021 – February 2023.
Bipolar I Disorder: LYBALVI TRx grew 4000% (from 67 to 2747). Market leader TRx decreased 5% (from 403,533 to 382,746).
Schizophrenia: LYBALVI TRx grew 2723% (from 104 to 2936). Market leader TRx decreased 8% (from 191,565 to 176,232).
Analysis includes market basket of products that have an indication consistent with an FDA-approved indication for LYBALVI. This information is not intended to suggest clinical comparability of products and should not be seen as making a claim regarding safety or efficacy.
Bipolar I Disorder
Efficacy and Safety
Explore efficacy and safety data to see if LYBALVI may be right for your appropriate patients.
Schizophrenia
Efficacy and Safety
Explore efficacy and safety data to see if LYBALVI may be right for your appropriate patients.
Dosing and
Opioid Use Warning
Get information about recommended dosing for your appropriate patients with schizophrenia or bipolar I disorder and learn about the opioid use warning.
Request a Rep and Register
for Updates
Sign up to get LYBALVI updates, information, and resources to help support your patients, or request an appointment with a sales representative.
Access Support for
Your Patients
Help your patients get access to treatment with assistance from LYBALVI Care Support.
Patient
Resources
Get LYBALVI educational materials and useful resources to inform your practice and support your patients.
As of February 2023:
Over 115,000 prescriptions
filled for LYBALVI*
Over 25,000 patients
treated with LYBALVI†
Over 9,300 prescribers
have written a prescription for LYBALVI‡
This information should not be seen as making a claim regarding safety or efficacy.
*Source: IQVIA Total Prescriptions (TRx) Data October 2021 – February 2023.
†Source: IQVIA Physician (XPonent) Data October 2021 – February 2023
(Patients with at least one prescription filled).
‡Source: IQVIA Patient Data October 2021 – February 2023.
IQVIA expressly reserves all rights, including rights of copying, distribution and republication.